| Pfizer Pumps $200M Into CStone for Rights to PD-L1 Cancer Drug in China | Frank Vinluan | 09/30/20 | New York |
| Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More | Frank Vinluan | 09/11/20 | National |
| GSK Expands Synthetic Lethality Scope With $120M Ideaya Bio Alliance | Frank Vinluan | 06/16/20 | San Francisco |
| Schrödinger Sets Course for IPO to Support Growing Internal Pipeline | Frank Vinluan | 01/14/20 | New York |
| The Winners of the 2019 Xconomy Awards Boston Are… | Jeff Bauter Engel | 09/12/19 | Boston |
| The Finalists for the 2019 Xconomy Awards Are … | Angela Shah | 07/10/19 | Boston |
| The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski | Ben Fidler | 03/11/19 | National |
| Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More | Alex Lash | 02/15/19 | National |
| GV Taps Ex-Agios CEO Schenkein to Lead Life Science Investments | Frank Vinluan | 02/11/19 | San Francisco |
| ASH 2018: Three Up, Two Down as Big Blood Disease Meeting Rolls On | Ben Fidler | 12/03/18 | National |
| ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More | Alex Lash | 11/26/18 | National |
| New VARI Initiative Aims to Understand How Metabolism Drives Disease | Sarah Schmid Stevenson | 10/08/18 | Detroit Ann Arbor |
| Catch CRISPR 2.0, RNA-Targeting Drugs & More At “Disruptors” on Oct. 17 | Ben Fidler | 09/26/18 | Boston |
| Bio Roundup: A Gene Editing 1st, China Rises, Schenkein Steps Away | Ben Fidler | 09/07/18 | National |
| After a High-Speed Decade, Agios CEO David Schenkein to Step Aside | Ben Fidler | 09/04/18 | Boston |
| Bio Roundup: An Alzheimer’s Head-Scratcher, OUTBio, GSK & Gilead Shakeups | Ben Fidler | 07/27/18 | National |
| Bio Roundup: Big Bucks For Calico, Data Dumps & The IPO Wave Rolls On | Ben Fidler | 06/29/18 | National |
| Rheos Medicines Launches, Backed by $60M for Immunometabolism R&D | Frank Vinluan | 03/22/18 | Boston |
| CMS Starts to Cover Broad Cancer DNA Tests, Boosting Foundation, Thermo | Ben Fidler | 03/19/18 | Boston |
| Will Foundation’s FDA, CMS Nod Help Cancer DNA Tests Break Through? | Ben Fidler | 12/01/17 | Boston |
| Bio Roundup: CRISPR Advances, Obamacare Lives, FDA Nods & More | Ben Fidler | 08/04/17 | National |
| With FDA Nod, Agios, Celgene Get Speedy OK For Blood Cancer Drug | Ben Fidler | 08/01/17 | Boston |
| Stifling Immigration Is “Retrograde”: Highlights From “What’s Hot” | Ben Fidler | 05/17/17 | Boston |
| Check Out What’s Hot in Boston Biotech on May 11: Saver Rate Ends Today | Ashley Gentile | 04/06/17 | Boston |
| To Infinity and Beyond: Julian Adams on Missteps and His New Job | Ben Fidler | 04/03/17 | Boston |
| Harvard’s Verdine Aims to Retire, Become Full-Time FogPharma CEO | Ben Fidler | 02/23/17 | Boston |
| Just Four Months After Series A, Delinia Sells to Celgene For $300M | Ben Fidler | 01/26/17 | Boston |
| Bio Roundup: NY Rises, Prez Inks Cures, Ophthotech Crashes & More | Alex Lash | 12/16/16 | National |
| After FDA Hold, Agios Quickly Scraps One Anemia Drug, Turns to Another | Ben Fidler | 12/15/16 | Boston |
| ASH Roundup: CAR-T Shuffle, Hemophilia Updates, Checkpoint Progress & More | Ben Fidler | 12/06/16 | National |
